| The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors SB Willingham, JP Volkmer, AJ Gentles, D Sahoo, P Dalerba, SS Mitra, ... Proceedings of the National Academy of Sciences 109 (17), 6662-6667, 2012 | 1586 | 2012 |
| Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47 MP Chao, S Jaiswal, R Weissman-Tsukamoto, AA Alizadeh, AJ Gentles, ... Science translational medicine 2 (63), 63ra94-63ra94, 2010 | 806 | 2010 |
| Anti-CD47 antibody–mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response D Tseng, JP Volkmer, SB Willingham, H Contreras-Trujillo, JW Fathman, ... Proceedings of the National Academy of Sciences 110 (27), 11103-11108, 2013 | 667 | 2013 |
| Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies K Weiskopf, AM Ring, CCM Ho, JP Volkmer, AM Levin, AK Volkmer, ... Science 341 (6141), 88-91, 2013 | 521 | 2013 |
| Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy AA Barkal, K Weiskopf, KS Kao, SR Gordon, B Rosental, YY Yiu, ... Nature immunology 19 (1), 76-84, 2018 | 426 | 2018 |
| CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer K Weiskopf, NS Jahchan, PJ Schnorr, S Cristea, AM Ring, RL Maute, ... The Journal of clinical investigation 126 (7), 2610-2620, 2016 | 389 | 2016 |
| Cancer immunotherapy targeting the CD47/SIRPα axis K Weiskopf European journal of cancer 76, 100-109, 2017 | 345 | 2017 |
| Asterless is a scaffold for the onset of centriole assembly NS Dzhindzhev, QD Yu, K Weiskopf, G Tzolovsky, I Cunha-Ferreira, ... Nature 467 (7316), 714-718, 2010 | 331 | 2010 |
| Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma B Edris, K Weiskopf, AK Volkmer, JP Volkmer, SB Willingham, ... Proceedings of the National Academy of Sciences 109 (17), 6656-6661, 2012 | 296 | 2012 |
| Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer HE Kohrt, R Houot, K Weiskopf, MJ Goldstein, F Scheeren, D Czerwinski, ... The Journal of clinical investigation 122 (3), 1066-1075, 2012 | 280 | 2012 |
| Macrophages are critical effectors of antibody therapies for cancer K Weiskopf, IL Weissman MAbs 7 (2), 303-310, 2015 | 275 | 2015 |
| Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity NG Ring, D Herndler-Brandstetter, K Weiskopf, L Shan, JP Volkmer, ... Proceedings of the National Academy of Sciences 114 (49), E10578-E10585, 2017 | 262 | 2017 |
| CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies HE Kohrt, R Houot, MJ Goldstein, K Weiskopf, AA Alizadeh, J Brody, ... Blood, The Journal of the American Society of Hematology 117 (8), 2423-2432, 2011 | 257 | 2011 |
| Targeting CD137 enhances the efficacy of cetuximab HE Kohrt, AD Colevas, R Houot, K Weiskopf, MJ Goldstein, P Lund, ... The Journal of clinical investigation 124 (6), 2668-2682, 2014 | 199 | 2014 |
| Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy A Chhabra, AM Ring, K Weiskopf, PJ Schnorr, S Gordon, AC Le, HS Kwon, ... Science translational medicine 8 (351), 351ra105-351ra105, 2016 | 179 | 2016 |
| Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps S Mitra, AM Ring, S Amarnath, JB Spangler, P Li, W Ju, S Fischer, J Oh, ... Immunity 42 (5), 826-838, 2015 | 165 | 2015 |
| A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells EC Piccione, S Juarez, J Liu, S Tseng, CE Ryan, C Narayanan, L Wang, ... MAbs 7 (5), 946-956, 2015 | 148 | 2015 |
| A nonpeptidic cathepsin S activity-based probe for noninvasive optical imaging of tumor-associated macrophages M Verdoes, LE Edgington, FA Scheeren, M Leyva, G Blum, K Weiskopf, ... Chemistry & biology 19 (5), 619-628, 2012 | 117 | 2012 |
| Myeloid cell origins, differentiation, and clinical implications K Weiskopf, PJ Schnorr, WW Pang, MP Chao, A Chhabra, J Seita, M Feng, ... Myeloid Cells in Health and Disease: A Synthesis, 857-875, 2017 | 107 | 2017 |
| Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors GW Krampitz, BM George, SB Willingham, JP Volkmer, K Weiskopf, ... Proceedings of the National Academy of Sciences 113 (16), 4464-4469, 2016 | 93 | 2016 |
